HomeCompareRLHPF vs ABBV

RLHPF vs ABBV: Dividend Comparison 2026

RLHPF yields 232.09% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RLHPF wins by $289.98M in total portfolio value
10 years
RLHPF
RLHPF
● Live price
232.09%
Share price
$0.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$290.08M
Annual income
$157,009,017.79
Full RLHPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RLHPF vs ABBV

📍 RLHPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRLHPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RLHPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RLHPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RLHPF
Annual income on $10K today (after 15% tax)
$19,727.99/yr
After 10yr DRIP, annual income (after tax)
$133,457,665.12/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RLHPF beats the other by $133,436,609.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RLHPF + ABBV for your $10,000?

RLHPF: 50%ABBV: 50%
100% ABBV50/50100% RLHPF
Portfolio after 10yr
$145.09M
Annual income
$78,516,894.78/yr
Blended yield
54.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RLHPF
No analyst data
Altman Z
1.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RLHPF buys
0
ABBV buys
0
No recent congressional trades found for RLHPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRLHPFABBV
Forward yield232.09%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$290.08M$102.3K
Annual income after 10y$157,009,017.79$24,771.77
Total dividends collected$275.49M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RLHPF vs ABBV ($10,000, DRIP)

YearRLHPF PortfolioRLHPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$33,909$23,209.40$11,550$430.00+$22.4KRLHPF
2$109,836$73,552.95$13,472$627.96+$96.4KRLHPF
3$340,184$222,659.37$15,906$926.08+$324.3KRLHPF
4$1,008,502$644,504.92$19,071$1,382.55+$989.4KRLHPF
5$2,864,784$1,785,687.02$23,302$2,095.81+$2.84MRLHPF
6$7,805,957$4,740,637.98$29,150$3,237.93+$7.78MRLHPF
7$20,424,598$12,072,224.24$37,536$5,121.41+$20.39MRLHPF
8$51,375,308$29,520,988.41$50,079$8,338.38+$51.33MRLHPF
9$124,369,753$69,398,173.63$69,753$14,065.80+$124.30MRLHPF
10$290,084,654$157,009,017.79$102,337$24,771.77+$289.98MRLHPF

RLHPF vs ABBV: Complete Analysis 2026

RLHPFStock

RLH Properties, S.A.B. de C.V. engages in the acquisition, development, and management of hotels and resorts. It operates 6 hotels comprising 1,266 rooms; and 2 hotels with approximately 235 rooms, as well as owns approximately 202 villas. The company was founded in 2013 and is based in Mexico City, Mexico.

Full RLHPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RLHPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RLHPF vs SCHDRLHPF vs JEPIRLHPF vs ORLHPF vs KORLHPF vs MAINRLHPF vs JNJRLHPF vs MRKRLHPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.